Table 9.
Summary of performance data collected in a study to compare 2 vaccination programs in feedlot calves at ultra-high risk of developing undifferentiated fever/bovine respiratory disease
| Experimental group
|
||||
|---|---|---|---|---|
| Performance variable | MLV3-BT2a | MLV4-BT1b | Sx̄c | P-value |
| Average daily gain (kg/animal/d) | ||||
| Live weight basis | 1.33d | 1.28d | 0.01 | 0.008 |
| Carcass weight basis | 1.40 | 1.35 | 0.01 | 0.004 |
| Dry matter intake to gain ratio | ||||
| Live weight basis | 6.38 | 6.49 | 0.05 | 0.176 |
| Carcass weight basis | 6.05 | 6.16 | 0.05 | 0.168 |
Animals in the MLV3-BT2 group received a modified-live viral vaccine containing infectious bovine rhinotracheitis virus (IBRV), type I and II bovine viral diarrhea virus (BVDV), and a Mannheimia haemolytica (MH) and Pasteurella multocida (PM) bacterin-toxoid [Express 3 and Pulmo-guard PHM-1; respectively, Boehringer Ingelheim (Canada) Burlington, Ontario]. There were 6 pens and 1942 animals in the MLV3-BT2 group
Animals in the MLV4-BT1 group received a modified-live viral vaccine containing IBRV, type I BVDV, bovine respiratory syncytial virus, and parainfluenza-3 virus and a MH bacterin-toxoid (Bovi-Shield 4 and One Shot; respectively, Pfizer Animal Health, Pfizer Canada, Kirkland, Quebec). There were 6 pens and 1940 animals in the MLV4-BT1 group
The standard error of the mean calculated from the analysis of variance
Numbers presented for each group are least squares means from the analysis of variance